Sugi Predict

Sugi Predict / Targets / PGK2

PGK2

Phosphoglycerate kinase 2 (EC 2.7.2.3) (Phosp · P07205 · PGK2 on Sugi Atlas →

7,702 patent compounds predicted against PGK2, 3,966 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL578288 SCHEMBL578288 0.56 11/20
SCHEMBL1617420 SCHEMBL1617420 0.67 10/20
SCHEMBL241659 SCHEMBL241659 0.55 10/20
SCHEMBL578007 SCHEMBL578007 0.54 10/20
SCHEMBL241492 SCHEMBL241492 0.50 10/20
SCHEMBL240726 SCHEMBL240726 0.54 9/20
SCHEMBL1585512 SCHEMBL1585512 0.48 9/20
SCHEMBL578080 SCHEMBL578080 0.48 9/20
SCHEMBL2637236 SCHEMBL2637236 0.42 9/20
SCHEMBL342414 SCHEMBL342414 0.48 8/20
SCHEMBL2171583 SCHEMBL2171583 0.48 8/20
SCHEMBL2637218 SCHEMBL2637218 0.44 8/20
SCHEMBL1235045 SCHEMBL1235045 0.69 7/20
SCHEMBL916486 SCHEMBL916486 0.61 7/20
SCHEMBL1542035 SCHEMBL1542035 0.61 7/20
SCHEMBL1486788 SCHEMBL1486788 0.59 7/20
SCHEMBL2574093 SCHEMBL2574093 0.55 7/20
SCHEMBL633379 SCHEMBL633379 0.55 7/20
SCHEMBL361741 SCHEMBL361741 0.50 7/20
SCHEMBL915502 SCHEMBL915502 0.50 7/20

Clinical trials — most relevant to PGK2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes PHASE4COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
European Celecoxib Trial in Primary Breast Cancer PHASE3COMPLETED
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer PHASE1/PHASE2RECRUITING
Biological Effects of Quercetin in COPD Phase II PHASE2UNKNOWN
Bempedoic Acid Therapy for Polycystic Kidney Disease PHASE2NOT_YET_RECRUITING
Metformin Plus/Minus Fasting Mimicking Diet to Target the Metabolic Vulnerabilities of LKB1-inactive Lung Adenocarcinoma PHASE2UNKNOWN
Acetylcarnitine and Insulin Sensitivity PHASE2COMPLETED
Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients PHASE2COMPLETED
STAR Cape+BKM120 MBC With Brain Met PHASE2COMPLETED
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers PHASE1COMPLETED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer PHASE1COMPLETED
Dried Fruit and Postprandial Glycemia Trial nanUNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation nanCOMPLETED
McArdle Disease Treatment by Ketogenic Diet nanCOMPLETED
Fluorodeoxyglucose Positron Emission Tomography (FDG PET) Findings in Patients With Phenylketonuria Before and After KUVAN Therapy nanCOMPLETED
Insulin Resistance in Relation to Hyperthyroidism and Hypothyroidism nanUNKNOWN
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients nanUNKNOWN
Biologic Mechanisms for Pain Variation After Physical Activity in Osteoarthritis nanCOMPLETED
The Role of Sugars in Fat Accumulation in the Liver nanRECRUITING
Effect of Acute Fructose Load in Human nanCOMPLETED
Effects of Dual-Source Carbohydrate Intake and Liver Glycogen Repletion After Overnight Fasting. nanNOT_YET_RECRUITING
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes nanCOMPLETED
Vulvodynia: Identification of Potential Relevant Biomarkers nanCOMPLETED
Role of Amino Acids and Genetic Disorder in Pathogenesis of Heart Failure nanUNKNOWN
Implementing Preemptive Pharmacogenomic Testing for Colorectal Cancer Patients in a Community Oncology Clinic nanCOMPLETED
Alternative Substrates in the Critically Ill Subject nanCOMPLETED
Biomarkers in Exhaled Breath Condensates in Acute Lung Injury: Early Detection and Outcome Predictors nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PGK2 binder may also engage these)

ProteinNameSimilarity
Q4R3K4 — 1.000 Q4R3K4 →
Q6RI85 — 1.000 Q6RI85 →
Q8MIF7 — 1.000 Q8MIF7 →
Q60HD8 — 1.000 Q60HD8 →
P00559 — 1.000 P00559 →
P29408 — 1.000 P29408 →
A5A6K4 — 1.000 A5A6K4 →
O61471 — 0.999 O61471 →
Q3T0P6 — 0.998 Q3T0P6 →
Q7SIB7 — 0.998 Q7SIB7 →
O60101 — 0.998 O60101 →
P51903 — 0.997 P51903 →
Q7ZA46 — 0.997 Q7ZA46 →
P09041 — 0.996 P09041 →
P41756 — 0.996 P41756 →
P29405 — 0.995 P29405 →
Q9GPM4 — 0.995 Q9GPM4 →
P50310 — 0.995 P50310 →
P24590 — 0.995 P24590 →
P16617 — 0.995 P16617 →
Q5NVB5 — 0.994 Q5NVB5 →
Q01604 — 0.994 Q01604 →
PGK1 Phosphoglycerate kinase 1 0.994 landscape →
O74233 — 0.994 O74233 →
O94123 — 0.994 O94123 →
P09411 — 0.994 P09411 →
P08966 — 0.994 P08966 →
P41759 — 0.993 P41759 →
Q6FKY1 — 0.993 Q6FKY1 →
P62421 — 0.993 P62421 →